RxDoctor Payments Data

Otto Bonin, NP

Nurse Practitioner · Zachary, LANPI 1558368316

Payments from drug & device makers

$4,512in general payments, 2019–2025

Across 266 payments — averaging $16.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • GSK$375
  • Lilly USA, LLC$275
  • AstraZeneca$249
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$241
  • Pfizer$225
  • plus $2K from 34 others

What the payments were for

  • Food & beverage$4,512100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$4,512 in reported general payments places this provider in the 90th percentile of 969 nurse practitioner providers in Louisiana.

See all nurse practitioner providers in Louisiana

Medicare billing

Part B allowed, 2024
$53,576
Medicare patients
110
Services billed
31,335

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide131$152,424
Trelegy ElliptaFluticasone/Umeclidin/Vilanter94$80,293
EliquisApixaban99$71,571
OzempicSemaglutide52$70,323
JanuviaSitagliptin Phosphate39$41,050
XareltoRivaroxaban57$36,396
VraylarCariprazine Hcl20$27,608
LinzessLinaclotide37$26,619
JardianceEmpagliflozin34$25,001
FarxigaDapagliflozin Propanediol13$16,871
Tresiba Flextouch U-200Insulin Degludec17$9,977
VascepaIcosapent Ethyl21$6,919
Tresiba Flextouch U-100Insulin Degludec13$5,886
Pantoprazole Sodium572$4,276
Sildenafil Citrate19$4,186

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$275$152,424131 claims
GSKTrelegy Ellipta$375$80,29394 claims
PfizerEliquis$225$71,57199 claims
Novo NordiskOzempic$216$70,32352 claims
AbbVieVraylar, Linzess$1,238$54,22757 claims
MerckJanuvia$14$41,05039 claims
Boehringer IngelheimJardiance$69$25,00134 claims
AstraZenecaFarxiga$249$16,87113 claims
Arbor Pharmaceuticals, Inc.Edarbi$48$3,41115 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 969 nurse practitioner providers in Louisiana.

Other nurse practitioner in Zachary

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →